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Metabolic and inflammatory pathways cross-
talk at many levels, and, while required for ho-
meostasis, interaction between these pathways
can also lead to metabolic dysregulation under
conditions of chronic stress. Thus, we hypothe-
sized that mechanisms might exist to prevent
overt inflammatory responses during physio-
logical fluctuations in nutrients or under nutri-
ent-rich conditions, and we identified the six-
transmembrane protein STAMP2 as a critical
modulator of this integrated response system
of inflammation and metabolism in adipocytes.
Lack of STAMP2 in adipocytes results in aber-
rant inflammatory responses to both nutrients
and acute inflammatory stimuli. Similarly, in
whole animals, visceral adipose tissue of
STAMP2/ mice exhibits overt inflammation,
and these mice develop spontaneous metabolic
disease on a regular diet, manifesting insulin re-
sistance, glucose intolerance, mild hyperglyce-
mia, dyslipidemia, and fatty liver disease. We
conclude that STAMP2 participates in integrat-
ing inflammatory and metabolic responses and
thus plays a key role in systemic metabolic
homeostasis.
INTRODUCTION
Cells and organisms must strike an appropriate balance
between nutrient sufficiency and surplus. Adequate
amounts of nutrients must be obtained in order for them
to survive and function normally. On the other hand,
chronic nutrient overload can lead to obesity as well as
to an array of associated metabolic disorders, including
insulin resistance, hepatosteatosis, type 2 diabetes, and
cardiovascular disease. This cluster of chronic diseases
now constitutes the largest global health threat.In the past decade, it has been clearly recognized that
metabolic diseases, particularly obesity and diabetes,
have strong inflammatory underpinnings (Wellen and Ho-
tamisligil, 2005; Hotamisligil, 2006). For example, obesity
is associated with a state of chronic low-grade inflamma-
tion (Hotamisligil et al., 1993), and insulin action can be in-
hibited by several inflammatory signaling molecules, in-
cluding the JNK, IKK, and SOCS family proteins
(Emanuelli et al., 2000; Mooney et al., 2001; Yuan et al.,
2001; Hotamisligil, 2006). Experiments with loss-of-func-
tion mouse models have demonstrated the central role
of these inflammatory pathways in metabolic diseases
(Uysal et al., 1997; Yuan et al., 2001; Hirosumi et al.,
2002; Howard et al., 2004; Arkan et al., 2005; Cai et al.,
2005). Inflammatory signaling pathways can be activated
in obesity both by cytokines such as TNFa as well as by
nutrients such as lipids and glucose, particularly when
blood or cellular levels are chronically elevated (Brownlee,
2001; Hotamisligil, 2006).
Given the potential for nutrients to stimulate inflam-
matory pathways and the importance of keeping these
pathways in check, we hypothesized that previously un-
recognized counterregulatory mechanisms might exist to
protect cells from activation of inflammatory pathways
during physiological fluctuations in nutrient exposure or
in nutrient-rich conditions. We reasoned that a factor
participating in such a coordinating mechanism between
nutrient and inflammatory responses would be expected
to meet several criteria: (1) the gene product should be
present in tissue types responsible for nutrient clearance
fromblood, such as adipose tissue; (2) expression or activ-
ity should be regulated by both nutritional and inflam-
matory stimuli; (3) the factor should regulate inflammatory
signaling components and/or gene expression (cells or
tissues lacking such a factor would then exhibit excess
or prolonged inflammation in response to challenges by
both nutrients and inflammatory mediators); (4) the factor
should regulate cellular metabolism, and its absence
should result in impaired cellular metabolic function; and
(5) through regulation of metabolic function in particular
cell types and organs, the factor should also impact sys-
temic metabolism.Cell 129, 537–548, May 4, 2007 ª2007 Elsevier Inc. 537
Figure 1. Regulation of STAMP2 Expres-
sion
(A) Regulation of adipose tissue STAMP2
mRNA expression in ob/ob and ob/ob-
TNFa/ treated with vehicle or thiazolidine-
diones, assessed by northern blot.
(B) Northern blot showing tissue distribution of
STAMP2 mRNA in WT mice.
(C) STAMP2 expression by northern blot during
differentiation of 3T3-L1 preadipocytes into
adipocytes.
(D) STAMP2 expression in adipocyte (Adi) and
stromal-vascular (S-V) fractions of white adi-
pose tissue (WAT).
(E) Activation of the STAMP2 promoter. Re-
sponsiveness of the 2 kb STAMP2 promoter
to transcription factors CEBPa, LXRa, and
PPARgwas analyzed by luciferase reporter as-
says in HeLa cells. T0901317 is a synthetic LXR
agonist, and pioglitazone (Pio) is an agonist of
PPARg.
(F) Regulation of STAMP2 expression in re-
sponse to 4mM or 25mM glucose or 6 hr treat-
ments of 100 nM insulin, 300 mM oleic acid,
20% serum, or 10 ng/ml TNFa, assessed by
quantitative RT-PCR (qPCR). Data indicates
mean ± SEM. ** indicates p < 0.005.
(G) Regulation of STAMP2 expression by WAT
in fed and fasted conditions (northern blot). (F =
Fed; S = Starved).
(H) Immunostaining for adipose-tissue
STAMP2 protein in fed and fasted mice in sam-
ples from visceral depot.In this study, we identify six-transmembrane protein of
prostate 2 (STAMP2) as a factor meeting these criteria.
STAMP2, also known as TNF-induced adipose-related
protein (TIARP) or six-transmembrane epithelial antigen
of prostate 4 (STEAP4), belongs to a family of six-
transmembrane proteins, termed either the STAMP or
STEAP family (Moldes et al., 2001; Korkmaz et al., 2005;
Ohgami et al., 2006). Three of the four family members, in-
cluding STAMP2, have recently been characterized as
metalloreductases playing a role in cellular import of iron
and copper (Ohgami et al., 2006). Here, we report that
STAMP2 coordinates inflammatory responses with meta-
bolic function in adipocytes and is essential for mainte-
nance of systemic metabolic homeostasis.
RESULTS
Regulation of STAMP2 Expression in Cultured
Adipocytes and Adipose Tissue
In attempts to identify factors that might participate in co-
ordinated regulation of metabolism and inflammation, we
first performed a screen for genes differentially regulated
in obese mice that were (1) lacking a key inflammatory
molecule, TNFa, or receptors responsible for TNF action
or (2) treated with insulin-sensitizing thiazolidinedione
(TZD) drugs (Wellen et al., 2004). We then narrowed our
focus to genes that are exclusive to or highly enriched in538 Cell 129, 537–548, May 4, 2007 ª2007 Elsevier Inc.adipose tissue and identified STAMP2 as a candidatemol-
ecule. Adipose-tissue STAMP2 expression was reduced
in obese animals either deficient in TNFa function or
treated with TZD, demonstrating that STAMP2 is regu-
lated by TNFa in vivo (Figure 1A). Consistent with our find-
ings, previous reports have demonstrated that STAMP2 is
expressed in adipocytes in vitro and is regulated by cyto-
kines (Moldes et al., 2001; Fasshauer et al., 2004). To fur-
ther explore the regulation of STAMP2, we examined its
expression in mouse tissues and in cultured adipocytes
during differentiation. STAMP2 is expressed in white adi-
pose tissue (WAT) at more abundant levels than any other
tissue examined (Figure 1B). In addition, STAMP2 expres-
sion was absent in preadipocytes but strongly induced
during adipocyte differentiation in 3T3-L1 cells, in agree-
ment with earlier studies (Moldes et al., 2001; Figure 1C).
In adipose tissue, the principal source of STAMP2 expres-
sion was also found in mature adipocytes, although a low-
level expression was detected in the stromal-vascular
fraction (Figure 1D).
Adipocyte differentiation is predominantly coordinated
by PPARg and C/EBP family-member transcription fac-
tors, with PPARg and C/EBPa engaging in a positive feed-
back loop to drive differentiation forward (Rosen et al.,
2000). Since STAMP2 expression is induced during
differentiation, we asked whether one or both of these
adipogenic transcription factors might control STAMP2
expression. While no portion of the 2 kb 50 promoter se-
quences that we examined responded to PPARg even in
the presence of synthetic agonists, STAMP2 promoter ac-
tivity was strongly induced by CEBPa (Figure 1E). Interest-
ingly, we found that the promoter was also responsive to
LXRa, another transcription factor implicated in adipocyte
gene expression, although this was smaller in magnitude
compared to CEBPa (Figure 1E). Since PPARg does not
appear to directly regulate the STAMP2 promoter, it is
likely that reduced expression of STAMP2 seen in the
TZD-treated ob/ob WAT is indirect (Figure 1A). Together,
these results establish STAMP2 as a differentiation-
dependent molecule present in adipocytes in vitro and
in vivo, thus fulfilling our first criterion.
In our model, we have postulated that regulatory mole-
cules would respond to nutritional status and inflamma-
tory signals. To investigate whether STAMP2 expression
is regulated by nutritional conditions in vitro, we treated
3T3-L1 adipocytes with various stimuli and examined
STAMP2 expression. While glucose and insulin treat-
ments alone produced minimal regulation of STAMP2
expression in adipocytes, high serum and fatty acids
markedly induced STAMP2 levels (Figure 1F). Similarly,
treatment with TNFa increased STAMP2 levels in adipo-
cytes to levels comparable to or higher than those ob-
tained by these nutritional stimuli (Figure 1F).
We next sought to determine whether fluctuations in nu-
tritional status would also result in regulation of STAMP2
expression in adipose tissue depots in vivo. To that end,
we examined STAMP2 expression during feeding and
fasting in lean as well as genetically obese, leptin-deficient
(ob/ob) mice. In lean mice, STAMP2 expression was ele-
vated in the fed, as compared to fasted, state, particularly
in visceral adipose depot (VWAT), a site often considered
as the most relevant depot for metabolic pathologies
(Figure 1G; Despres and Lemieux, 2006). STAMP2 protein
levels, as assessed by immunohistochemistry, correlated
with the RNA levels (Figure 1H). In ob/ob mice, however,
nutritional regulation of STAMP2 expression was com-
pletely lost (Figure 1G). A similar loss of nutritional regula-
tion was also observed in high-fat diet-induced obesity
(Figure S1). Thus, STAMP2 expression is responsive to
both nutritional and inflammatory signals both in cultured
adipocytes and adipose tissue.
Aberrant Inflammatory and Metabolic Responses
in the Absence of STAMP2 In Vitro
To investigate whether STAMP2 has a direct role in mod-
ulating inflammation in adipocytes, we utilized RNAi to
reduce STAMP2 expression in 3T3-L1 adipocytes. After
administration of siRNA, we confirmed efficient (R80%)
knockdown of STAMP2 mRNA expression (Figure 2A).
Protein levels, as assessed by immunofluorescence anal-
ysis, were reduced (Figure 2B). Finally, we demonstrated
by western blot that Flag-tagged STAMP2 exogenously
expressed in adipocytes can be almost entirely sup-
pressed using this siRNA-based experimental system
(Figure 2C).Next, we examined expression of inflammatory cyto-
kine production in adipocytes in the presence of either
inflammatory (TNFa-stimulation) or nutritional (hypergly-
cemic) challenges. Upon treatment with TNFa, we ob-
served significantly greater induction of IL-6 expression
in STAMP2-knockdown versus control cells (Figure 2D).
When cultured in a physiological low-glucose medium,
STAMP2 knockdown and control cells expressed similar
amounts of interleukin-6 (IL-6) mRNA. However, in high-
glucose conditions, STAMP2-deficient cells expressed
approximately twice as much IL-6 mRNA as control cells
(Figure 2E). We also measured secretion of IL-6 protein
and found that in high-glucose conditions, IL-6 secretion
was indeed augmented in the absence of STAMP2
(Figure 2F). Interestingly, this effect appears to be some-
what selective, as other TNFa-regulated genes, such as
MCP-1 and IL-1b, as well as the TNFR1 and TNFR2,
were not differentially regulated in these conditions (data
not shown).
Abnormal inflammatory activity might be expected to
negatively influence metabolic homeostasis. To address
this possibility, we examined insulin action in 3T3-L1 adi-
pocytes transfected with STAMP2-specific or control
siRNA. Indeed, STAMP2 deficiency resulted in moderate
but consistent impairment of insulin-stimulated glucose
transport in adipocytes (Figure 2G). We then assessed
whether this is due to alterations in the insulin-induced
translocation of the glucose transporter Glut4 to the
plasma membrane in the absence of STAMP2. An ectop-
ically expressed Glut4 (tagged with a myc epitope in the
first exofacial loop as well as GFP, for tracking) exhibited
reduced insulin-stimulated translocation to the plasma
membrane in the absence of STAMP2 (Figure 2H). This re-
duction was significant when STAMP-deficient cells with
detectable Glut4 translocation were quantitated com-
pared to controls (Figure 2I). We also examined the insu-
lin-receptor-signaling pathway. In control cells, insulin
stimulation results in dose-dependent increases in the
tyrosine phosphorylation of insulin receptor and serine
phosphorylation of Akt. In STAMP2-deficient cells, the
effects of insulin were modestly but significantly reduced
(Figure S2A). These results indicate that STAMP2 defi-
ciency impairs insulin action and disrupts glucose trans-
port in adipocytes.
Increased Inflammation and Reduced Insulin Action
in the Genetic Absence of STAMP2 In Vivo
To confirm the function of STAMP2 in regulating adipose
tissue inflammation and metabolism in vivo, we examined
mice with homozygous targeted null mutations in the
STAMP2 locus. We confirmed by northern blot analysis
in adipose tissue that these mice did in fact lack STAMP2
expression (Figure 3A). STAMP2/mice were fully viable
and fertile and reproduced at the expected Mendelian ra-
tios with no visible abnormalities. At 5–6 months of age,
wild-type (WT) and STAMP2/ mice were sacrificed
and tissues harvested for analysis of gene expression,
biochemical studies, and histological analysis. In additionCell 129, 537–548, May 4, 2007 ª2007 Elsevier Inc. 539
Figure 2. STAMP2 Deficiency Results in Elevated Inflammatory Gene Expression and Reduced Insulin Action in Cultured Adipo-
cytes
(A) Efficient knockdown of STAMP2 mRNA confirmed by qPCR following electroporation of control and STAMP2-specific siRNAs into 3T3-L1 adi-
pocytes under high and low glucose (Glc).
(B) Knockdown of STAMP2 protein confirmed by immunofluorescence.
(C) Knockdown of Flag-STAMP2 expressed in 3T3-F442A adipocytes confirmed by western blot analysis.
(D) IL-6 expression measured by qPCR after overnight incubation in high-glucose serum-free medium and stimulation with TNFa (10 ng/ml, 6 hr).
(E) IL-6 expression in adipocytes in high- and low-glucose conditions.
(F) IL-6 secretion measured by ELISA in cell supernatants collected under the same conditions as in (E).
(G) Insulin-stimulated 3H-2-deoxyglucose uptake in cultured adipocytes upon suppression of STAMP2.
(H) Insulin-stimulated myc-Glut4-GFP translocation to the plasma membrane assessed by immunocytochemistry and confocal microscopy.
(I) Quantitation of experiments shown in panel (H) in three independent experiments. All data represent mean ± SEM. Open bars indicate control
siRNA; closed bars indicate STAMP2 siRNA. * indicates p < 0.05; ** indicates p < 0.005.to confirming the absence of STAMP2, we also examined
expression of the three other STAMP family members for
possible compensatory regulation. Interestingly, all of
the STAMP family members are expressed in adipose tis-
sue, but only STEAP3 was consistently and significantly
upregulated in the absence of STAMP2 (Figure 3B). On
the other hand, STEAP1 and STAMP1 tended to be sup-
pressed in STAMP2/ VWAT (Figure 3B).
Next, inflammatory gene expression in both subcutane-
ous and visceral WAT depots was examined. We found
that inflammation due to STAMP2 deficiency was much
more pronounced in this in vivo setting compared to that
observed in 3T3-L1 adipocytes. In STAMP2/ animals,
expression of multiple inflammatory factors, including
IL-6, TNFa, MCP-1, haptoglobin, and SOCS-3, were sig-
nificantly elevated in VWAT (Figure 3C). In contrast to
VWAT, alterations in inflammatory gene expression in
SWAT in STAMP2/ animals were minimal; while there540 Cell 129, 537–548, May 4, 2007 ª2007 Elsevier Inc.was a trend for higher levels of some genes, these differ-
ences were subtle and did not reach statistical signifi-
cance (Figure 3C). Thus, the primary site of STAMP2 ex-
pression and regulation in vivo coincides with that of
marked inflammatory abnormalities in its absence.
The VWAT depot also manifested striking histological
differences between STAMP2/ and WT animals.
Though no clear differences in adipocyte cell size were
observed, in STAMP2/ mice, VWAT, but not SWAT,
contained markedly increased numbers of mononuclear
cells among adipocytes (Figure 3D). Recent evidence
has indicated that adipose tissue, particularly in obesity,
can accumulate macrophages (Weisberg et al., 2003; Xu
et al., 2003). To test whether the mononuclear cells pres-
ent in the VWAT of STAMP2/ mice might be infiltrating
macrophages, we tested for the presence of the macro-
phage-specific antigen F4/80 by immunohistochemistry
(Figure 3E). There was strong staining for F4/80 in the
Figure 3. Adipose Tissue of STAMP2/
Mice Exhibits Elevated Expression of
Inflammatory Genes, Accumulation of
Mononuclear Cells, and Oxidative Stress
Tissues were harvested from 5- to 6-month-old
mice on standard diet.
(A) STAMP2 mRNA expression in the adipose
tissue of STAMP2/ (KO) and WT mice exam-
ined by northern blot analysis.
(B) Expression of STAMP family members in
VWAT examined by qPCR.
(C) Inflammatory gene expression in VWAT and
SWAT as examined by qPCR. (Open bars indi-
cate WT; closed bars indicate STAMP2/).
(D) Tissue sections from WT and STAMP2/
mice were stained with hemotoxylin and eosin.
(E) F4/80 antigen positivity in WT and
STAMP2/ VWAT, detected by immunohisto-
chemistry.
(F) Gene expression related to oxidative stress
was evaluated in VWAT (open bars indicate
WT; closed bars indicate STAMP2/).
(G) Levels of TBARS in VWAT (n = 5 animals/ge-
notype). All data are presented asmean ±SEM.
For all qPCR experiments, 5 or 6 animals in
each genotype were examined, and mRNA ex-
pression of each gene was normalized to 18S
rRNA levels. * indicates p < 0.05; ** indicates
p < 0.005; and *** indicates p < 0.0005.Cell 129, 537–548, May 4, 2007 ª2007 Elsevier Inc. 541interstitial space between adipocytes in VWAT of most
STAMP2/ animals, suggesting that STAMP2/ VWAT
indeed becomes infiltrated by macrophages, defined as
F4/80-positive cells. In contrast, we did not observe no-
ticeable macrophage accumulation in any WT mice. Inter-
estingly, similar to inflammatory gene expression, macro-
phage infiltration was also seen only in STAMP2/ VWAT
and was absent from SWAT (Figures 3D and 3E).
Metabolic dysfunction in adipocytes and adipose tissue
is frequently associated with oxidative stress (Furukawa
et al., 2004; Houstis et al., 2006). We asked whether this
might be a potential mechanism involved in the
STAMP2-deficient model, and, therefore, we measured
expression of antioxidant genes in adipose tissues. These
experiments demonstrated that expression of catalase,
glutathione-S-transferase (GST), and superoxide dismu-
tase 1 (SOD1) was significantly reduced in the VWAT of
mice lacking STAMP2, whereas NADPH oxidase 1 was
significantly upregulated (Figure 3F). These expression
patterns are similar to observations previously reported
in obesity (Furukawa et al., 2004). Interestingly, no signifi-
cant changes were observed in these genes in the subcu-
taneous adipose tissue (Figure S3A). To test whether
STAMP2/ mice might have increased oxidative stressin VWAT as compared to WT mice, we measured levels
of thiobarbituric acid reactive substances (TBARS) as an
indicator of lipid peroxidation. Indeed, STAMP2/ mice
displayed significantly higher levels of lipid peroxidation
in VWAT than WT mice (Figure 3G). These results suggest
that in the absence of STAMP2, adipose tissue is suscep-
tible to oxidative stress.
If our hypothesis that STAMP2 suppresses inflamma-
tion under nutrient-rich conditions is correct, then
STAMP2/ WAT may exhibit increased inflammatory re-
sponse to a nutritional challenge. To address this possibil-
ity, we administered intralipid and glucose into WT and
STAMP2/ mice and examined inflammatory gene ex-
pression in adipose tissue compared to saline-treated
control mice in both genotypes. Combined administration
of glucose and lipid stimulated expression of IL-6 and
SOCS-3 in both genotypes, although it did so to a signifi-
cantly greater extent in the adipose tissue of STAMP2/
mice (Figure 4A). These data support the model that even
a short-term nutritional challenge can stimulate an inflam-
matory response in WAT in vivo and that STAMP2 plays
a role in modulating this response. To determine whether
STAMP2 is also necessary for metabolic regulation in vivo,
we isolated primary adipocytes from WT and STAMP2/
Figure 4. Impaired Insulin Action in the
Visceral WAT of STAMP2/ Mice
(A) PBS or intralipid and glucose (LG) were in-
jected intraperitoneally into WT and
STAMP2/ mice followed by measurement
of IL-6 and SOCS-3 mRNA levels in VWAT by
qPCR. Data are pooled from two independent
experiments, shown as mean ± SEM.
(B) Glucose transport in primary adipocytes.
(C) Insulin-stimulated Akt phosphorylation in
VWAT and SWAT. Representative animals are
shown in the western blot, with each lane rep-
resenting one animal. Phosphorylation of Akt
normalized to total Akt protein was quantified
and both absolute (Figure S3) and fold insulin-
stimulated Akt phosphorylation were graphed,
with data pooled from two independent exper-
iments, represented as mean ± SEM.
Expression of (D) metabolic and (E) macro-
phage-specific genes in VWAT was deter-
mined by qPCR. For each gene 6–9 animals/
genotype were examined, shown as mean ±
SEM. For (B)–(E), open bars indicate WT, and
closed bars indicate STAMP2/. * indicates
p < 0.05; ** indicates p < 0.005; and *** indi-
cates p < 0.0005.mice and examined glucose transport. Adipocytes iso-
lated from STAMP2/ mice exhibited severely defective
insulin-stimulated glucose transport. Interestingly, defec-
tive glucose uptake was far more profound in the
STAMP2/ adipocytes obtained from the visceral depot,
although it was also reduced in subcutaneous adipocytes
(Figure 4B).
We next examined insulin receptor signaling in vivo. In
WT mice, insulin action, as measured by increased phos-
phorylation of Akt, was clear and uniform in both adipose
depots. In STAMP2/ mice, however, basal and insulin-
stimulated levels of Akt phosphorylation were rather
heterogeneousbetweenanimals, andbasal Akt phosphor-
ylation levels were overall elevated (Figures 4C and S3B).
Hence, insulin had a significantly impaired stimulatory im-
pact on Akt phosphorylation in the VWAT of STAMP2/
mice (Figure 4C). In contrast, insulin signaling in SWAT in
the same STAMP2/ mice was normal (Figure 4C). We
suggest that the alterations in insulin signaling may
contribute to the severe suppression of insulin-stimulated
glucose transport in visceral adipocytes in the absence of
STAMP2 but likely are not sufficient to account for the en-
tire defect. We also found significantly decreased expres-
sion of several genes critical formetabolic function, includ-
ing Glut4, adiponectin, fatty acid synthase (FAS), fatty acid
transporter 1, and PPARg, though others, such as FATP4
and leptin, were not significantly regulated (Figure 4D). It
is likely that reduced expression of Glut4 also contributes
to the pronounced glucose transport defect inSTAMP2/
visceral adipocytes. Since we have examined gene ex-
pression in the entire fat padwithout separating out adipo-
cytes specifically, it is possible that the increased pres-542 Cell 129, 537–548, May 4, 2007 ª2007 Elsevier Inc.ence of macrophages in adipose tissue may have
contributed to adipocyte-specific gene-expression pat-
terns. As would be anticipated, macrophage-specific
gene expression, such as Mac-1 and CD68, is also ele-
vated in the VWAT of STAMP2/ mice (Figure 4E).
STAMP2 Deficiency Causes Spontaneous Metabolic
Disease in Mice
We next asked whether STAMP2 deficiency may lead to
alterations in systemic metabolic homeostasis. To ad-
dress this, we examined body weight, systemic glucose
metabolism, and lipid levels in whole animals. Uponwean-
ing, mice were placed on a standard rodent diet and mon-
itored to 20 weeks of age. Throughout the experimental
period, there was minimal difference in total body weight
between genotypes which did not reach statistical signif-
icance at any age (Figure 5A). We also tested whether
STAMP2 deficiency might alter body composition in
mice by performing dual energy X-ray absorption (DEXA)
analysis. While no differences in adiposity were observed
at 2 months of age, by 5 months STAMP2/mice tended
to accumulate more body fat than WT mice (Figure 5B).
Subcutaneous (WT: 0.021 ± 0.002; KO: 0.032 ± 0.002
g/g body weight; p = 0.004) but not visceral (WT:
0.039 ± 0.003; KO: 0.041 ± 0.004 g/g body weight; p =
0.6) adipose-tissue weight was significantly higher in
STAMP2/mice. It is possible that the extra body fat later
on in life accumulates subcutaneously, rather than viscer-
ally, due to the severe defects in insulin action in visceral
fat inSTAMP2/mice. In addition, liver weight was signif-
icantly higher in STAMP2/ mice (WT: 0.043 ± 0.004;
KO: 0.057 ± 0.004 g/g body weight; p = 0.038).
Cell 129, 537–548, May 4, 2007 ª2007 Elsevier Inc. 543To gain additional insights into the metabolism of these
mice and possible reasons for the tendency to accumulate
body fat, we monitored 6-week-old STAMP2/ and WT
mice for 48 hr in metabolic cages that enable determina-
tion of both energy intake (eating) and output (metabolic
rate). Although there were no differences in food intake,
VO2 and VCO2 tended to be lower in STAMP2
/ mice,
suggesting that theymay have a lower metabolic rate (Fig-
ures S4A and S4B). There were also reduced rates of
physical activity in these animals, particularly during the
dark cycle (Figures S4C and S4D). These results suggest
that the principal cause of higher adiposity in STAMP2/
mice may be reduced energy expenditure.
Insulin resistance is a central feature of metabolic syn-
drome. To evaluate the status of insulin action, we first ex-
amined plasma insulin and glucose levels throughout the
experimental period. At 12 weeks of age, plasma insulin
levels were significantly elevated in STAMP2/ mice
Figure 5. Development of Metabolic Disease in STAMP2/
Mice
(A) WT (n = 11) and STAMP2/ (n = 9) mice were weighed weekly until
20 weeks of age.
(B) Percent body fat was measured in a separate group of mice aged 2
and 5 months using DEXA analysis.
(C) Every 4 weeks, blood was collected after a 6 hr fast. At 4, 12, and 20
weeks of age, serum insulin was measured by ELISA.
(D) Blood glucose was measured every 4 weeks after a 6 hr fast.
(E) Serum triglycerides and cholesterol were measured and (F) distri-
bution of lipoprotein particles was profiled at 12 weeks of age.
(G) Glucose- and (H) insulin-tolerance tests were performed on mice
aged 12 and 17 weeks, respectively. All data are presented as
mean ± SEM. In (A), (D), (G), and (H) squares indicate WT, and triangles
indicate STAMP2/; in (B), (C), and (E), open bars indicate WT, and
closed bars indicate STAMP2/. * indicates p < 0.05; ** indicates
p < 0.005; and *** indicates p < 0.0005.compared with WT mice, and this pattern was progres-
sively accentuated until the end of the experiment at 20
weeks (Figure 5C). Plasma glucose concentrations were
also slightly, but significantly, higher in the STAMP2/
mice compared to WT animals by 16 weeks of age, and
they continued to increase at 20 weeks (Figure 5D). Higher
blood glucose concentrations in the presence of hyperin-
sulinemia in the STAMP2/ mice are indicative of sys-
temic insulin resistance.
We also determined steady-state levels of plasma lipids
to assess whether STAMP2 deficiency causes dyslipide-
mia. Plasma triglycerides and cholesterol concentrations
were moderately but significantly elevated at 12 weeks
of age in STAMP2/ mice compared to control animals
(Figure 5E). While total levels of cholesterol were elevated,
FPLC analysis revealed no clear difference in lipoprotein
particle distribution (Figure 5F). Plasma-free fatty-acid
levels did not differ between genotypes (WT: 0.82 ± 0.1;
KO: 0.84 ± 0.4 mM).
To explore systemic insulin sensitivity further in this
model, we next performed insulin- and glucose-tolerance
tests (ITT and GTT, respectively) in each genotype. Glu-
cose-disposal curves upon administration of insulin were
significantly reduced in STAMP2/ mice compared to
WT controls, demonstrating the presence of insulin resis-
tance (Figure 5H). Similarly, in GTT, the glucose-disposal
patterns observed in STAMP2/ mice indicates signifi-
cant glucose intolerance (Figure 5G). These results clearly
show that STAMP2 deficiency disturbs systemic insulin
action in the absence of additional stress.
Given the clear impairment in systemic glucose metab-
olism in STAMP2/ mice, we suspected that insulin ac-
tion at metabolic tissues other than adipose tissue may
also be impaired. To address whether liver function may
be altered in STAMP2/ mice, we first investigated insu-
lin action at this site in vivo. In these experiments, we ob-
served a severe impairment of insulin-receptor signaling in
the livers of STAMP2/ mice (Figure 6A).
Our results indicate that insulin action is impaired in
STAMP2-deficient mice in at least two metabolically rele-
vant tissues, visceral adipose tissue and liver tissue. An
important question for understanding the role of STAMP2
in regulation of systemic metabolism is which tissues are
critical in mediating the development of systemic insulin
resistance. To elucidate the organs responsible for the
systemic metabolic phenotype we performed hyperinsuli-
nemic-euglycemic clamp experiments in WT and
STAMP2/ mice. As expected, no differences in body
weight were observed between genotypes in the animals
used for the clamp experiments, either at the time of cath-
eterization surgery or experiment (Figure S5A). Experi-
ments were performed with 4-month-old STAMP2/
mice in the fasted state, and blood glucose values were
normalized during the clamp (Figure S5B). Glucose-infu-
sion rate was significantly lower in STAMP2/ mice
than WT controls throughout the duration of the clamp,
confirming systemic insulin resistance (Figure 6B). The
rate of glucose disposal was also lower in STAMP2/
animals but did not achieve statistical significance (p =
0.06, Figure 6C). Hepatic glucose production was signifi-
cantly higher in STAMP2/mice in both basal and clamp
conditions, and ability to suppress hepatic glucose pro-
duction in hyperinsulinemic conditions was significantly
compromised, demonstrating the presence of liver insulin
resistance (Figures 6D and 6E). We also tested whether in-
sulin-stimulated glucose uptake into muscle and fat were
altered in these mice by determining tissue content of
14C-2-deoxyglucose tracer. As expected and in agree-
ment with the rest of our data, glucose uptake into adipose
tissuewas impaired in theabsenceofSTAMP2 (Figure 6G).
Muscle glucose uptake was also significantly reduced in
STAMP2/ animals (Figure 6F). These results suggest
that the moderate reduction observed in the rate of glu-
Figure 6. Liver Insulin Action and Hyperinsulinemic-Euglyce-
mic Clamp
(A) Insulin action in the liver following insulin injection into the portal
vein of anesthetized mice. Each lane represents one animal.
(B) Hyperinsulinemic-euglycemic clamp experiments. Rate of glucose
infusion was higher inWT than inSTAMP2/mice over the 2 hr course
of the clamp.
(C) Average glucose infusion rates (GIR) and rate of disposal (Rd) were
calculated.
(D) Hepatic glucose production at basal and clamp conditions as well
as (E) percent suppression of hepatic glucose production by hyperin-
sulinemic clamp were calculated.
(F) Muscle and (G) adipose-tissue glucose uptake during the clamp
were assessed by measuring uptake of a 14C-2-deoxyglucose tracer.
* indicates p < 0.05; and ** indicates p < 0.005. Data are graphed as
mean ± SEM. For parts (C)–(G), open bars indicate WT; closed bars in-
dicate STAMP2/. For part (B), open circles indicate WT; closed
squares indicate STAMP2/.544 Cell 129, 537–548, May 4, 2007 ª2007 Elsevier Inc.cose disposal in STAMP2/ mice is likely to be biologi-
cally significant since both muscle and fat are significantly
impaired in glucose uptake capacity. Overall, the results of
these clamp experiments indicate that both liver glucose
production and peripheral glucose disposal contribute to
the systemic insulin resistance in STAMP2/ animals.
In STAMP2/ mice, liver sections exhibited notable
fatty accumulation, particularly as the animals aged
(Figure 7A). At 6 months of age total liver triglyceride con-
tent in STAMP2/ mice was significantly elevated
(Figure 7B). Expression of FAS and stearoyl CoA desatur-
ase (SCD-1), enzymes critical in fatty acid and triglyceride
synthesis, respectively, was significantly elevated in the
livers of STAMP2/ mice (Figure 7C). As the signs of in-
sulin resistance precede the time of marked steatosis,
we next asked whether the defective insulin signaling in
liver might be the result of an effect mediated by altered
endocrine activity of adipose tissue in STAMP2 defi-
ciency. To explore this possibility, rat Fao liver cells were
treated with conditioned medium that was collected
from 3T3-L1 adipocytes transfected with either control
or STAMP2 siRNA. Liver cells cultured with conditioned
medium from STAMP2-deficient adipocytes exhibited re-
duced insulin signaling compared to controls, suggesting
that the absence of STAMP2 in adipocytes may regulate
insulin sensitivity in liver cells (Figure S2B). We next exam-
ined plasma levels of various adipokines, reasoning that
increased inflammatory gene expression in adipose tissue
may be reflected in increased plasma levels, thus contrib-
uting to systemic effects. Although elevated adipose ex-
pression of some inflammatory cytokines did not translate
into detectably higher levels in circulation in these exper-
iments, both leptin and resistin were found to be signifi-
cantly elevated in STAMP2/ mice (Table 1). Resistin
has been implicated in impairing glucose homeostasis,
particularly through regulation of hepatic glucose produc-
tion (Steppan and Lazar, 2004); hence, it is possible that
elevated resistin levels may contribute to some of the liver
phenotypes of the STAMP2/ mouse.
If STAMP2 indeed serves as a regulatory factor to pre-
serve metabolic function, we would predict that under
conditions of metabolic stress, such as obesity, the ab-
sence of STAMP2would exacerbate the phenotype. Alter-
natively, and particularly considering the loss of regulation
of STAMP2 expression in obesity (Figure 1G), it is possible
that STAMP2 action is only relevant during relatively short-
term or acute challenges. To evaluate this, we decided to
examine the function of STAMP2 in ob/ob mice, a model
of severe obesity with moderate hyperglycemia. We suc-
ceeded in generating a small group of STAMP2/ob/ob
mice and compared them to age-matched ob/ob controls.
Although the two groups were similar in total body weight
at 12 weeks of age (Figure 7D), the ob/ob mice lacking
STAMP2 had significantly higher body-fat percentage
(Figure 7E). On the C57Bl/6 genetic background, ob/ob
mice develop only mild hyperglycemia. Remarkably, how-
ever, STAMP2/ob/ob mice had extremely high blood
glucose levels, averaging nearly 500 mg/dl after a 6 hr
Figure 7. Liver Lipid Accumulation in
STAMP2/ Mice and Absence of
STAMP2 Exacerbate Metabolic Pheno-
type of ob/ob Mice
(A) Liver sections were stained with hemotoxy-
lin and eosin.
(B) Quantitation of liver triglyceride, with ob/ob
liver used as a control.
(C) FAS and SCD-1 expression determined by
qPCR in liver at 6 months of age.
(D) Generation of ob/ob (n = 4) and
STAMP2/ob/ob (n = 5) mice. In 12-week-
old mice, (D) body weight was similar between
genotypes, though (E) body fat was signifi-
cantly higher in mice lacking STAMP2.
(F) Blood glucose after a 6 hr fast was signifi-
cantly higher in the STAMP2/ob/ob mice.
(G) H & E staining of liver sections showed
higher lipid accumulation with larger lipid drop-
lets in the mice lacking STAMP2. All bar graph
data represent mean ± SEM.fast (Figure 7F). Comparison of liver sections also indi-
cated even more pronounced lipid accumulation in the
STAMP2/ob/ob mice (Figure 7G).
Taken together, these results demonstrate that
STAMP2 deficiency is sufficient to spontaneously recapit-
ulate many cardinal features of the metabolic syndrome,
including inflammation, insulin resistance, glucose intoler-
ance, mild hyperglycemia, dyslipidemia, and fatty infiltra-
tion of liver, and can markedly exacerbate the metabolic
abnormalities of the ob/ob model of severe obesity.
DISCUSSION
The results of this study position STAMP2 in a critical role
of modulating inflammatory responses and protecting
metabolic function in adipocytes. Recent studies have in-
Table 1. Adipokine Levels (pg/ml) in 12-Week-OldWild-
Type and STAMP2/ Mice
WT STAMP2/
Adiponectin 9182 ± 423 8375 ± 461
Leptin 6577 ± 1461 17040 ± 4265a
Resistin 1271 ± 165 1826 ± 177a
TNFa 8.52 ± 0.38 8.77 ± 0.21
IL-6 ndb nd
MCP-1 nd nd
a p < 0.05
b nd = not detectabledicated the relevance of nutrients in activating inflamma-
tory pathways (Hotamisligil, 2006). Much evidence has
shown the role of hyperglycemia in mediating diabetic
complications, and recently the ability of glucose to acti-
vate oxidative stress and inflammatory pathways in adipo-
cytes has also been shown (Brownlee, 2001; Lin et al.,
2004). Additionally, free fatty acids can activate inflamma-
tory responses and impair insulin action in adipocytes
(Nguyen et al., 2005). Thus, excess nutrients can be dam-
aging, and we suggest that STAMP2 may play an impor-
tant role in the adipocyte defense arsenal against nutrient
surplus. Our results demonstrate not only that acute nutri-
tional challenges can cause excessive inflammation in the
adipose tissue of STAMP2/mice but that even in condi-
tions of ad lib feeding on a standard diet, STAMP2 is es-
sential for prevention of excessive inflammation and pro-
tection of adipocyte insulin sensitivity and systemic
glucose homeostasis. A critical objective for the future
will be to elucidate the mechanisms by which STAMP2
mediates these effects. We suggest that over time the ac-
cumulation of small cellular stresses due to daily changes
and fluctuations in nutrients in STAMP2/mice may lead
to the activation of inflammatory pathways and inhibition
of insulin action resulting in systemic metabolic deteriora-
tion over the long term.
The findings that STAMP2 both protects against exces-
sive inflammation and is also upregulated under inflamma-
tory and nutrient-rich conditions may appear paradoxical
at first. Our results suggest that STAMP2 acts in a regula-
tory role and that it does so not to block activation of in-
flammatory pathways but to restrict the degree of their ac-
tivity. This is exemplified in the regulation of STAMP2 by
TNFa. TNFa induces both STAMP2 and inflammatoryCell 129, 537–548, May 4, 2007 ª2007 Elsevier Inc. 545
cytokine expression; yet, in the absence of STAMP2, the
ability of TNFa to promote IL-6 expression is more potent.
We suggest that STAMP2 acts in a similar regulatory
capacity in response to acute nutritional challenges or
chronic hyperglycemia. In strong support of our model,
ob/obmice lacking STAMP2 exhibit an exacerbated met-
abolic phenotype as compared to ob/ob mice with intact
STAMP2 function. It is important to note, however, that
ob/obmice experiencemuchmore rapid and severe onset
of obesity than would be typical for either mice fed a high-
fat diet or formost human obesity. It remains possible that,
in a more gradual onset of obesity, STAMP2 may play
a less important or different role, and, hence, additional
andmore extensive studies in other mouse obesity and di-
abetes models are warranted.
High adipose-tissue expression of STAMP2 also fits
well with this model since adipocytes are critical in the
management of excess nutrients. It is notable that the tis-
sue distribution that we observe in mice is somewhat dif-
ferent than the published rat tissue distribution, which
shows high STAMP2 expression in liver and kidney in ad-
dition to adipose tissue (Moldes et al., 2001). In humans,
STAMP2 is known to be expressed highly in heart, pla-
centa, lung, liver, and prostate, though adipose tissue
has not been examined (Korkmaz et al., 2005). In applying
these data to other models or humans, it will be important
to consider possible differences between species in terms
of STAMP2 expression and function.
STAMP2 belongs to a family of four mammalian pro-
teins, which have been described within recent years un-
der several different names, including STAMP1 (STEAP2),
STAMP2 (TIARP; STEAP4), STEAP, and STEAP3 (pHyde;
TSAP6; Hubert et al., 1999; Steiner et al., 2000; Moldes
et al., 2001; Korkmaz et al., 2002; Passer et al., 2003;
Korkmaz et al., 2005; Ohgami et al., 2005). While all mem-
bers have been characterized in the prostate, STAMP2 is
the only family member that has been previously reported
to be expressed in adipocytes and adipose tissue (Moldes
et al., 2001). All of these proteins contain six-transmem-
brane domains and, except for STEAP, a long N-terminal
tail predicted to have NADP+/NADPH oxidoreductase ac-
tivity. These proteins have recently been characterized as
metalloreductases, capable of facilitating cellular uptake
of both iron and copper (Ohgami et al., 2006). The rele-
vance of STEAP3 in the physiological regulation of iron
metabolism has been confirmed in vivo, and mice lacking
STEAP3 suffer from anemia (Ohgami et al., 2005). A critical
question for future studies is what role, if any, does the
metalloreductase domain play in STAMP2’s metabolic ef-
fects. One attractive hypothesis could be that STAMP2 as
a ferrireductase may be facilitating iron uptake into the ad-
ipocyte for use in intermediarymetabolism since a number
of metabolic components involved in glucose and lipid
metabolism require iron for their activity, including lipid
desaturases, aconitases, and cytochromes. An intriguing
possibility may be that STAMP2 action might be involved
in providing iron to the mitochondria for the production of
iron-sulfur clusters required for the respiratory complexes546 Cell 129, 537–548, May 4, 2007 ª2007 Elsevier Inc.of the electron transport chain. Deficient electron-trans-
port-chain function could result in reactive oxygen species
(ROS) production, which is known to impact both inflam-
matory pathways and insulin signaling. Much additional
work will be required to evaluate these possibilities.
We find that STAMP2 deficiency in mice results in im-
paired insulin action in fat, liver, and muscle, all tissues
that are critical for glucose homeostasis. Although
STAMP2 expression is highest in WAT in mice, it is also
present in liver and muscle and may have primary effects
at all three locations. Of course, changes in the endocrine
function of adipose tissue may also contribute to or even
entirely mediate the liver and systemic phenotypes, and,
thus, further studies addressing the role of STAMP2 in
the regulation of adipocyte secretory function are also
warranted. Much evidence has been documented to indi-
cate that factors secreted from adipocytes play critical
roles in the regulation of liver and systemic metabolism
(Rajala and Scherer, 2003). Prior studies have suggested
that STAMP family members may have direct roles in se-
cretory processes. STAMP1 and STAMP2 colocalize
with markers for Golgi and early endosomes, and live
cell imaging reveals that these proteins cycle between
the plasma membrane and an internal compartment
(Korkmaz et al., 2002, 2005). In addition, STEAP3 has
been shown to faciliate the secretion of translationally
controlled tumor protein (TCTP) through a nonclassical
pathway (Amzallag et al., 2004). If STAMP2 also serves
such a function, it might impact other organs, particularly
liver, due to the proximity of VWATs to this organ. Thus, it
will be worthwhile to investigate whether STAMP2 may
regulate the endocrine function of the adipocyte both at
the levels of gene expression and protein secretion.
Finally, this study also highlights the differences in biol-
ogy between visceral and subcutaneous WAT and the
unique involvement of STAMP2 in this distinction. Clearly,
the visceral depot has a much stronger phenotype than
the subcutaneous depot in STAMP2 deficiency. This sug-
gests that the visceral depot is either more susceptible to
environmental insults such as hyperglycemia due to fun-
damental metabolic differences between the depots or
is more exposed to such stressors, perhaps due to differ-
ences in vascularization or circulation. In addition to the
clinical association between visceral obesity and meta-
bolic syndrome, there are differences in gene-expression
patterns between the visceral and subcutaneous depots
(Lefebvre et al., 1998; Despres and Lemieux, 2006). Inter-
estingly, a recent study has also shown that, upon expo-
sure to nutrients, visceral adipose tissue is much more re-
sponsive than the subcutaneous depot for expression of
secreted molecules (Einstein et al., 2005). Our data pro-
vide a potential molecular locus critical in the differential
regulation of these depot-specific responses.
We suggest that the findings presented in this manu-
script identify a unique role for STAMP2 in the coordina-
tion of inflammation and metabolism and contribute a
critical molecular component to our understanding ofmet-
abolic homeostasis and its relationship with inflammation.
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Mice
STAMP2/ mice were purchased from Deltagen, Inc. (San Carlos,
CA; Deltagen tracking number ZBB519), where they were generated
by gene targeting into embryonic stem cells derived from 129P2/
OlaHsd mice and injected into C57Bl/6 blastocysts. We obtained
two heterozygous breeding pairs (Deltagen), which we used to gener-
ateWT andSTAMP2/mice.Micewere given free access to the stan-
dard rodent diet [PicoLab Mouse Diet 20, containing 9% fat by weight
(21.6% kcal from fat)]. Age-matched lean and obese ob/obmale mice
used in feeding/fasting experiment were obtained from Jackson Labs.
To generate STAMP2/ob/ob mice, STAMP2/ mice were inter-
crossed with ob+/ mice, and F1 double heterozygotes were then
used to generate the STAMP2/ob/ob and ob/ob genotypes. The In-
stitutional Animal Care and Use Committee (Harvard School of Public
Health) approved all studies.
Metabolic Studies
For glucose-tolerance tests, male 12-week-old WT (n = 9) and
STAMP2/ (n = 10) mice were fasted overnight (14 hr) and injected in-
traperitoneally (i.p.) with 2 g/kg glucose. For insulin-tolerance tests,
male 17-week-old WT (n = 4) and STAMP2/ (n = 5) mice were fasted
for 6 hr and injected i.p. with 0.75 IU/kg insulin. For both, blood was
collected from the tail vein at the indicated times, and glucose was
measured using an Ascensia glucometer. Body fat was measured in
mice anethesthetized with ketamine/xylazine using DEXA (age
2 months: n = 4 WT, n = 6 KO; age 5 months: n = 6 WT, n = 7 KO).
Injections of Insulin and Lipid/Glucose Administration
3-month-old male mice were anesthetized with tribromoethanol, and
2 IU/kg insulin or PBSwas infused into the portal vein. After 3min, liver,
VWAT, and SWAT were collected in that order and immediately frozen
in liquid nitrogen. Lysates were prepared and used for western blot-
ting. Lipid and glucose administrations were done in 2-month-old
WT and STAMP2/ mice. After overnight fasting, mice were injected
i.p. with either 2 ml PBS or 2 ml 20% intralipid (gift of Baxter Health-
care, Deerfield, IL). After 4 hr, either PBS or 2 mg/kg glucose was
injected i.p., and 90min later animals were sacrificed. Tissues were re-
moved and immediately frozen in liquid nitrogen. Data are pooled from
two independent experiments, with a total of four mice/genotype re-
ceiving PBS and six mice/genotype receiving lipid and glucose.
Cell-Culture and Reporter Experiments
3T3-L1 preadipocytes were maintained in DMEM supplemented with
10% calf serum. To differentiate, cells were grown to confluence and
placed into induction medium (DMEM, 10% cosmic calf serum,
5 mg/ml insulin, 0.5 mM IBMX, 1 mM Dexamethazone, and 10 mM
TZD). After 2 days, cells were switched into differentiation medium
(DMEM, 10% cosmic calf serum, and 5 mg/ml insulin) until they were
used for experimentation. For insulin-signaling experiments, cells
were serum starved overnight, treated with insulin for 100 s, and imme-
diately frozen in liquid nitrogen prior to preparation of protein lysate.
For RNAi experiments, siRNA specific to STAMP2 (target sequence:
AAGCAGCATCCAAGTCTGACA) and nonspecific control were syn-
thesized byQiagen. AnAmaxa Nucleofector was used to electroporate
siRNA into 3T3-L1 adipocytes 5 days after inducing differentiation. Ex-
periments were performed 36–48 hr after electroporation. For reporter
assays, a 2 kb fragment of 50 STAMP2 promoter region was cloned into
a reporter plasmid. Promoter activity was evaluated in HeLa cells
(ATCC) cultured in DMEM supplemented with 10% fetal calf serum.
Cells were seeded in 6-well plates, grown to 50% confluency, and
transfected with plasmid DNA with the indicated transcription factors
and ligands for LXR (T0901317, 10 mM), PPARg (pioglitazone,
1.5mM), or DMSO followed by luciferase assays as described previ-
ously (Slagsvold et al., 2001). Further details are provided in the Sup-
plemental Data.Quantitative PCR
RNAwas isolated from tissues and cells using Trizol (Invitrogen). cDNA
was synthesized using either Thermoscript (Invitrogen) or iScript
(BioRad). Q-PCR was performed using a BioRad iCycler. Primer
sequences may be found in the Supplemental Data.
Liver Triglycerides
Lipid extraction was performed using the Bligh-Dyer method (Bligh
and Dyer, 1959). Briefly, livers were homogenized in chloroform:
MeOH: H2O (1:2:0.8) at room temperature. Samples were spun, and
supernatants were saved. Equal amounts of chloroform and water
were added to supernatant. Samples were vortexed and centrifuged.
Chloroform layer was collected, and samples were dried completely
in vacuum oven. Samples were resuspended in 90% isopropanol:
10% Triton-X. Triglyceride concentration was measured using Sigma
Kit TR0100 per manufacturer’s instructions.
Hyperinsulinemic-Euglycemic Clamp Studies
Surgery was performed to catheterize the jugular vein of 4-month-old
WT (n = 8) and STAMP2/ (n = 7) mice. After a 4 day recovery period,
clamp experiments were performed as previously described (Ozcan
et al., 2006). To determine [3H]-glucose and 2-[14C]-DG concentra-
tions, plasma was deproteinized with ZnSO4 and Ba(OH)2, dried to re-
move 3H2O, resuspended in water, and counted in scintillation fluid for
detection of 3H and 14C. The plasma concentration of 3H2O was calcu-
lated by the difference between 3H counts with and without drying. Tis-
sue 2-[14C]-DG-6-phosphate (2-DG-6-P) content was determined in
homogenized samples that were subjected to an ion-exchange col-
umn to separate 2-DG-6-P from 2-[14C]-DG. Calculations and experi-
mental details are described in the Supplemental Data.
Supplemental Data
Supplemental Data include Experimental Procedures, References,
and five figures and can be found with this article online at http://
www.cell.com/cgi/content/full/129/3/537/DC1/.
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